Oral icotrokinra sustains UC response through 76 weeks
NASHVILLE, Tenn. — Investigational oral interleukin-23 inhibitor icotrokinra sustained efficacy and favorable tolerability through week 76 in patients with moderately to severely active ulcerative colitis, according to data presented here. Findings from a long-term extension of the phase 2b ANTHEM-UC trial, presented a
